Professor Jeremy Everett

Current and Previous Posts

Professor Jeremy Everett is Professor of Pharmaceutical Technologies and the Head of the Pharmaceutical, Chemical & Environmental Sciences department within the School of Science.

Professor Everett maintains a strong research interest in structure elucidation by NMR spectroscopy and in metabonomics. He conceived metabonomics, and named and defined it together with Professor Jeremy Nicholson (Imperial College, London), with whom he has a long-standing collaboration. He is a co-discoverer of pharmacometabonomics: which is the ability to predict the effects of drugs prior to dosing via metabolic profiling, and he is a co-inventor on a patent granted in the European Community on metabolic profiling in 2011. He is a Visiting Professor in the Department of Surgery and Cancer at Imperial College.

Professor Everett is a co-leader of the Medway Metabonomics Group (MMRG) together with Dr Ruey-Leng Loo from the School of Pharmacy and Professor Frank Pullen from the School of Science .

Professor Everett is the author of over 80 publications and reviews and a co-inventor on 3 patents, including one granted in Europe in 2011 on metabolic profiling. He has an H-index of 24 and has been cited in the literature over 2000 times, not including self-citations with an average of over 33 citations per publication.

Professor Everett consults for both major pharmaceutical and small biotech and research institutes on drug discovery. He is also a member of the Industrial Advisory Board for the EU-OpenScreen organisation.

Prior to his current position, Professor Everett held a variety of drug discovery technology leadership positions at Pfizer, and before that, SmithKline Beecham and Beecham Research Laboratories. These positions included responsibilities for analytical sciences, automated purification, biobanking, chemoinformatics, computational chemistry, ligand-based drug design, curation, management and provision of the compound screening file, data support and management, lead generation by high throughput screening, compound library design and production, indications discovery, structural biology, structure-based drug design and drug target analysis.

In addition to his technology leadership roles at Pfizer, Professor Everett co-led the screening collaboration between The Scripps Research Institute (TSRI) at Jupiter Florida and Pfizer with Professor Pat Griffin (TSRI, Florida); he also co-led with Professor Ray Stevens (TSRI, La Jolla) a collaboration on GPCR structural biology and he was a member of the Pfizer / TSRI Joint Steering Committee.

Professor Everett received both his BSc in chemistry and PhD in physical organic chemistry from Nottingham University. He was a Post-doctoral Fellow at McMaster University in Hamilton, Ontario, and a Research Associate at McGill University, Montréal.

Responsibilities within the University of Greenwich

• Member of University Learning and Quality Committee (LQC)
• Member of School of Science Senior Management Team (SMT)
• Member of School of Science School Board
• Member of School of Science Learning and Quality Committee
• Member of School of Science Programme Committee
• Member of School of Science Progression Committee
• Member of School of Science Plagiarism Investigation Committee

Course Participation

Medicinal Chemistry and Therapeutics, Pharmaceutics, Pharmaceutical Product Development and Manufacture

MPhil/PhD supervision

Ms Katharine Cunningham (Imperial College), Ms Dorsa Varshavi (University of Greenwich), Ms Tracey Yip (University of Kent); Ms Kallie Bladon (University of Kent)

Presentations

Upcoming Presentations

• "Shaping a Screening File for Effective Lead Discovery: New Concepts", EMBL Advanced Course on Computational Aspects of High Throughput Screening Planning and Analysis, Heidelberg, Germany, October 14 to 16, 2013

Public Lectures

School of Science Public Lecture, November 30th 2011: Professor Everett gave a presentation entitled “How do we Find New Drugs? Lifting the Veil on Drug Discovery” which covered the different origins of drugs, how they are discovered, how they work and why drug discovery is so hard, with highlighted examples from anti-bacterial, anti-viral and sexual health therapeutic areas.

School of Science Inaugural Professorial Lecture: Professor Everett spoke on 'Solving Molecular Mysteries: From Chemistry to Medicine' at the University of Greenwich, Chatham Maritime on May 10th 2011. The lecture was introduced by the Vice-chancellor of the University, Baroness Blackstone. Members of the public were joined by staff, students and guests from far and wide, including Germany, Switzerland and the USA.

The lecture covered a number of molecular mysteries before moving on to consider how we can predict the future! This work involved the use of NMR spectroscopy to analyse human biofluids such as urine to determine the profile of metabolites present in the urine. Mathematical analysis of human urine metabolite profiles was then used to determine how a person would react to a drug when dosed at a later time point. This completely new area of science is called pharmacometabonomics and it is predicted to play an important role in the development of personalised healthcare for people in the future.

Other Recent Lectures

• "From Metabonomics to Pharmacometabonomics: From Describing the Past to Predicting the Future", Discovery Summit 2013, Monte Carlo, Monaco, March 21 to 22, 2013
• “From Metabonomics to Pharmacometabonomics: From Describing the Past to Predicting the Future”, 2012 International Drug Discovery Science and Technology Conference, Nanjing, China, 08.11.12
• “Portfolio and Project Management in a Pharma-Academic Collaboration”, Project and Portfolio management in the Pharmaceutical Industry, Kakushin Group, International Webinar, 03.05.12
• “New Ways to Personalise Medicine in the Future: Pharmacometabonomics”, University of Greenwich with Kent and Medway National Institute of Health Research Comprehensive Local Research Network, Joint Research Day, Medway, UK, 18.04.12
• “Metabonomics, Pharmacometabonomics and the Future of Personalised Healthcare.”, NGP Drug Discovery Summit Europe, Bremen, German, 06.04.11
• “Strategies for Shaping a Screening File for Lead Discovery”, 9th Annual World Drug Discovery and Development Summit 2010, Copenhagen, Denmark, 26.10.10
• “The Pfizer-Scripps Research Institute Collaboration: What is it? How is it working and what value has been generated? 6th Annual Project and Portfolio Management in the Pharmaceutical Industry Conference, Milan, Italy, 28.09.10
• “The Pfizer – Scripps Screening Collaboration”, MipTec Drug Discovery Conference, Basel, Switzerland, 23.09.10
• “A New Hit Identification and Screening File Strategy for Pfizer”, Next Generation Pharmaceutical Summit- Drug Discovery, Vienna, Austria, 02.09.10
• “A New Hit Identification and Screening File Strategy for Pfizer”, 11th Annual Drug Discovery Leaders Summit, Montreux, Switzerland, 09.06.10
• “The Research Centres of Emphasis (RCoEs) and their impact upon effectiveness and efficiency in Pfizer Global R&D”, Sanofi-Aventis, Paris, 20.10.09
• “The Research Centres of Emphasis (RCoEs) and their impact upon effectiveness and efficiency in Pfizer Global R&D”, Discovery 2009, Monte-Carlo, Monaco, 25.3.09
• “Pfizer’s investment in the Research Centres of Emphasis and their impact upon effectiveness and efficiency in Pfizer Global R&D”, 3rd Annual Pharmaceutical PLM Conference, London, 30.1.09
• “The Impact of Technologies Current and Future on Drug Discovery Productivity: High Throughput Screening and Pharmacometabonomics”, Discovery 2008, Monte-Carlo, Monaco, 2.4.08
• “Strategic Challenges of Establishing a BioBank”, Biobanking and Biorepositories 2007, Amsterdam, The Netherlands, 27.4.07
• “Applications of nuclear magnetic resonance (NMR) in the pharmaceutical industry”, European Continuing Education College course on Modern Pharmaceutical Instrumental Analysis, London, 28.3.07

Research Interests

Professor Everett's research covers metabonomics, lead generation for drug discovery and molecular structure elucidation. He has over 80 publications and patents including two recent, landmark publications in PNAS and Nature on the discovery of pharmacometabonomics. Web of Science Impact Factor: h-index = 24, over 2000 non self-cited citations.

Selected recent publications

Pharmacometabonomics and Personalised Medicine, J. R. Everett, R. L. Loo and F. S. Pullen, manuscript submitted to Annals of Clinical Biochemistry (2013)

Plate-Based Diversity Screening: An Efficient Paradigm for High Throughput Screening (HTS) of a Large Screening File, A. Bell, J. Bradley, J. R. Everett, M. Knight, J. Loesel, J. Mathias, J. Mills, E. Sharp, C. Williams and T. P. Wood, Molecular Diversity, published on-line April 5th (2013), doi: 10.1007/s11030-013-9438-x

Report on the 10th Anniversary International Drug Discovery Science and Technology (IDDST) Conference – 2012, Nov 8th to 10th 2012, Nanjing, China, J.R. Everett, Expert Opinion on Drug Discovery, 8 (3), 357-361 (2013), doi:10.1517/17460441.2013.762353

Everett, J. R. et al, Shaping a Screening File for Maximal Lead Discovery Efficiency and Effectiveness: Elimination of Excess Molecular Redundancy and Undesirable Molecules, J. Chem. Inf. Model., 52 (11), 2937-2949 (2012), DOI: 10.1021/ci300372a, Publication Date (Web): October 14, 2012. e-Print available via: http://pubs.acs.org/articlesonrequest/AOR-CC6yfybq55CedW5DVJa2

Everett, J. R. et al Pharmacometabonomic characterization of xenobiotics and endogenous metabolic phenotypes that account for inter-individual variation in isoniazid-induced toxicological response, Journal of Proteome Research, 11 (9), 4630-4642 (2012), ePub August 9th 2012, DOI: 10.1021/pr300430u

Jeremy K. Nicholson, Jeremy R. Everett and John C. Lindon, Longitudinal pharmacometabonomics for predicting patient responses to therapy: drug metabolism, toxicity and efficacy, Expert Opinion in Metabolism and Toxicology, 8 (2): 135-9 (2012). ePub Jan 17th 2012, doi:10.1517/17425255.2012.646987

Everett, J. et al. 2009. Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism T. Proceedings of the National Academy of Sciences (PNAS), 106(34), pp. 14728–33. Available at: <www.pnas.org/cgi/doi/10.1073/pnas.0904489106>

The article was accompanied by a PNAS Highlight by Professor I. D. Wilson entitled Drugs, bugs, and personalized medicine: Pharmacometabonomics enters the ring, Proceedings of the National Academy of Sciences (PNAS), 106(34), pp. 14187–8 (2009).

Everett, J. (2007) Applications of Metabonomics in Clinical Pharmaceutical R&D. In: The Handbook of Metabonomics and Metabolomics, Lindon, J.C., Nicholson, J.K., and Holmes, E. (eds.) Amsterdam: Elsevier, pp. 279–87.

Everett, J. et al. (2006) Pharmaco-metabonomic phenotyping and personalised drug treatment. Nature, 440(7087), pp. 1073–77.

Patents

Clayton, T.A., Everett, J.R., Lindon, J.C., and Nicholson, J.K. Metabolic Phenotyping. WO 03/107270 A2, published 24.12.03.

Everett, J. et al. Molecular Markers of Oxidative Stress. PC32039, filed November 2003 ACCESSION NUMBER:2005:493754 HCAPLUS PRIORITY APPLN. INFO.: GB 2003-27743 A20031128; US 2004-558937 P20040402.